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ACRONYMS 
AcAc: Acetoacetate  
ACE: Angiotensin converting enzyme  
ACh: Acetylcholine 
AD: Alzheimer’s disease  
AMPA: Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
ApoE: Apolipoprotein E 
APP: Amyloid precursor protein 
ARIAs: Amyloid-related imaging abnormalities  
ATP: Adenosine triphosphate   
Aβ or Abeta: Amyloid beta  
BACE: Beta secretase 
BBB: Blood-brain barrier  
CMRgIc: Cerebral metabolic rate for glucose 
CNS: Central nervous system 
DMTs: Disease-modifying therapies 
ECE-1: Endothelin-converting enzyme-1 
FDA: Food and drug administration 
GABA: Gamma-amino butyric acid 
GLUTs: Glucose transporters  
GSK3β: Glycogen synthase kinase 3 β 
HDL: High-density lipoprotein  
HIV: Human immunodeficiency virus 
IDE: Insulin degrading enzyme  
IRS-1: Insulin receptor substrate-1  
KBs: Ketone bodies 
KD: Ketogenic diet  
LCHF: Low carbohydrate high fat 
LDL: Low-density lipoprotein   
MAP: Microtubule-associated protein 
MCI: Mild cognitive impairment 
MCTKD: Medium-Chain Triglyceride ketogenic diet  
MeDi: Mediterranean diet 
MetS: Metabolic syndrome 
MOAs: Mechanisms of action 
MUFA: Monounsaturated fatty acids  
NCEP ATP III: National Cholesterol Education Program Third Adult Treatment Panel 
NEP: Neprilysin 
NMDA: N-methyl-D-aspartate 
NFTs: Neurofibrillary tangles 
PHFs: Paired helical filaments 
PI3K: Phosphoinositide 3-kinase 
PUFA: Polyunsaturated fatty acids 
ROS: Reactive oxygen species 
βHB: β-hydroxybutyrate   
ABSTRACT 
Alzheimer’s disease (AD) is the most common cause of dementia and it has been 
estimated that the number of people suffering it is going to keep growing. AD is a chronic 
neurodegenerative disease that drives to a loss of connection between nerve cells and 
finally to their death. Although people are unlikely to experience the condition in exactly 
the same way, some symptoms like memory loss, confusion and difficulty with language 
are very common. The etiology of this disease is heterogeneous and wide since a lot of 
risk factors have been described, including modifiable lifestyle-related factors like diet. 
Different pathophysiological mechanisms have been hypothesized to explain AD origin 
and development. The most known one is the “amyloid hypothesis”, but some data 
support that the onset of the disease might be related to a brain metabolism 
abnormality. The decreased metabolic activity may increase amyloid beta 
(Aβ) deposition as a secondary response, and this would lead to the death of neurons 
causing dementia. At present, the available AD treatments show only modest 
symptomatic benefits, so a different approach has been considered: a ketogenic diet 
(KD). It is a high saturated fat/low carbohydrate diet that increases ketogenic bodies. By 
doing this, the brain can obtain energy from a different source and not only glucose.  
  
RESUM 
La malaltia d’Alzheimer és la causa més comú de demència i s’estima que la incidència 
seguirà augmentant. És una malaltia crònica neurodegenerativa que desencadena una 
pèrdua de connexió entre les cèl·lules nervioses i la mort d’aquestes. Tot i la varietat 
interindividual en la simptomatologia, s’han descrit símptomes comuns com la pèrdua 
de memòria, la confusió o la dificultat en el llenguatge. L’etiologia de malaltia 
d’Alzheimer és heterogènia i àmplia ja que s’han descrit molts factors de risc, entre els 
quals es troben factors modificables com la dieta. Pel que fa a les bases 
fisiopatològiques, la hipòtesi més establerta és l’amiloide. Tot i això, diferents estudis 
conclouen que l’inici de la malaltia és realment una disfunció en el metabolisme 
cerebral. Aquesta disminució en l’activitat metabòlica del cervell provocaria una 
acumulació de la proteïna beta amiloide (Aβ) com a resposta secundària i això 
comportaria la mort de les neurones i la demència. Els tractaments actuals de la malaltia 
només milloren lleugerament els símptomes i per això s’ha proposat un nou 
enfocament: la dieta cetogènica. Aquesta dieta és alta en greixos saturats i baixa en 
carbohidrats i això provoca la formació de cossos cetònics. Aquestes molècules 
proporcionen al cervell una font d’energia diferent a la glucosa.  
 
Alzheimer’s disease as a metabolic pathology: new approaches 
Final degree project 
- 1 - 
 
INTEGRATION OF THE AREAS 
Mental diseases, specially dementia, primarily afflict the elderly, and since we are an 
aging society, they have an important role. Most of these diseases are progressive so 
the symptoms get worse as the disease goes on. This kind of disorders should concern 
us because they affect the society in different aspects, from the relatives who have a 
mentally ill person in the family to the country’s economy. Furthermore, there is a 
huge need of effective treatments for these pathological conditions. This project is 
focused on Alzheimer’s disease (AD).  
Pharmacology is the science that studies how the chemical agents, both natural and 
synthetic, affect biological systems. It is often described as a bridge science because it 
includes knowledge and skills from a number of basic science disciplines including 
physiology or molecular biology. Due to the vast need of new treatments for AD and 
taking into account the objectives set below, the principal area of study is 
Pharmacology and Therapeutics. 
Biochemistry and Molecular Biology has been integrated in the development of this 
project because in order to suggest a treatment we should first understand what is 
happening at a molecular level. Pathophysiological bases of dementia and the 
molecular mechanisms that the brain uses to get energy are going to be considered in 
the present work. 
The other secondary study area is Nutrition and Bromatology. This field is also known 
as the science of the food. It has an important role in this project because it has been 
established that our lifestyle, including our diet, has an enormous impact in AD. The 
effects of diet in aging and neurodegeneration are becoming well-established and an 
early feature of AD is region-specific declines in brain glucose metabolism. Based on 
this knowledge, a new approach in AD treatment is going to be suggested.  
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1. INTRODUCTION 
1.1. ALZHEIMER’S DISEASE GENERALITIES 
The most common cause of dementia is Alzheimer’s disease (AD). This dementia 
involves the parts of the brain that control thought, memory and language, so it causes 
problems with memory, thinking and behaviour. AD is a progressive disease and this 
means that it begins slowly and the symptoms gradually get worse over time (4).  
During the course of the disease, proteins build up in the brain to form structures 
called “plaques” and “tangles”. This leads to the loss of connections between nerve 
cells, and eventually to their death and loss of brain tissue. Furthermore, people with 
AD also have a shortage of some important neurotransmitters so the transmit of 
information in the brain is reduced (3). 
It has been proposed that AD arises from the inability of certain parts of the brain to 
get enough energy from glucose. This disability can be compensated during decades 
until the point when the signs and symptoms become evident (5).  The most common 
symptom pattern begins with losing the ability to remember new information, but as 
damage spreads, individuals experience other difficulties.  The following are warning 
signs of AD (6): 
• Memory loss that disrupts daily life. 
• Challenges in planning or solving problems. 
• Difficulty completing familiar tasks at home, at work, or at leisure. 
• Confusion with time or place. 
• Trouble understanding visual images and spatial relationships. 
• New problems with words in speaking or writing. 
• Misplacing things and losing the ability to retrace steps. 
• Decreased or poor judgment. 
• Withdrawal from work or social activities. 
• Changes in mood and personality. 
As discussed below, the main problem regarding the treatment of AD is that when the 
first clinical manifestations appear, the pathogenesis of the disease is already in an 
advanced stage.  
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2. OBJECTIVES 
Alzheimer’s disease has a huge repercussion and it seems that it will continue like this, 
since the number of people affected grows every day. Despite of recent progress in 
understanding the neurobiology and pathophysiology of AD, no resolutive 
pharmacological treatments but only a few symptomatic drugs are currently available 
to patients. This lack of progress in AD treatment is disappointing given the enormous 
emotional, psychological and economic costs involved for patients and their 
caregivers. Due to the importance of this type of dementia in our society, the 
objectives of this final degree project are: 
1. To review the pathophysiological bases of dementia, mainly AD.  
2. To describe AD etiology, paying special attention to the importance of the diet. 
3. To study the molecular mechanisms that the brain uses to get energy. 
4. To analyse the link between the diet and AD, focusing on the role of carbohydrates. 
5. To review the current treatments and suggest new approaches in AD treatment. 
 
3. METHODS 
In order to achieve the objectives set before, an exhaustive research has been carried 
out. This bibliographical research includes primary, secondary and tertiary sources and 
took place from February 2018 to May 2018. The methodology mainly involves the 
analysis of scientific articles and their subsequent synthesis. The most used databases 
have been PubMed and Scifinder, and only free access articles facilitated by the Centre 
de Recursos per a l’Aprenentatge i la Investigació (CRAI) could have been consulted 
and included.  
First of all, a general search about dementia and AD was done. The aim was to be able 
to have a general knowledge about it, including types of dementia, risk factors and AD 
etiology data. As AD is the most frequent type of dementia, the work is focused on it.  
Secondly, a research about the pathophysiological bases of AD was done. The main 
keywords used during this search were “amyloid”, “hypothesis”, “metabolic 
syndrome”, “brain” and “energy deficit”.  
Last but not least, the bibliographical research was focused on the relationship 
between the diet, and the onset of the AD. Some scientific articles found in the 
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databases mentioned before were analysed. So as to enrich the information, an 
interesting book has been included in the bibliographical sources: Antídoto para el 




4.1.1. RISK FACTORS 
Each type of dementia has its own risk factors, but some of these factors are shared: 
4.1.1.1. Age 
It is the most significant risk factor for dementia. It is very unusual to see dementia in 
people under their 60s and it becomes very common in people older than 80 years 
old. Dementia affects one in six people between 80 and 85 years old, one in three 
above 85 years, and almost half of the people over 90 years old. 
4.1.1.2. Ethnicity 
People from certain ethnic communities are at higher risk of dementia than others. 
South Asian people (India and Pakistan, for example) seem to develop dementia more 
often than white Europeans. In this case we are talking specifically about vascular 
dementia. This higher risk can be explained by the fact that they are well known to be 
at a higher risk of stroke, heart disease and diabetes. Higher risk is likewise associated 
to people of African or African-Caribbean origin since they are known to be more 
prone to diabetes and stroke (7).  
4.1.1.3. Family history 
The genes’ role in the development of dementia is not yet fully understood, but there 
are some types of dementia that have a heritable component. That is to say that if the 
person has a close relative who has or had suffered AD, he or she will have more 
chances to develop it. The risk increases when the relative developed AD at a young 
age (less than 70 years old). Some studies have shown that a reason for cerebral 
amyloid deposition, which defines AD at the molecular level, is the APOE ε4 genotype, 
widely explained below in section 4.2.3 (8).  
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4.1.1.4. Others 
High blood pressure, smoking and diabetes may be risk factors for dementia. Having 
cardiovascular disease or type 2 diabetes increases a person’s risk of developing 
dementia by up to two times. There is also some evidence that depression could be a 
risk factor, but the relationship between dementia and depression is far from clear yet 
(9). Other medical conditions such as Parkinson’s disease, multiple sclerosis, human 
immunodeficiency virus (HIV) or Down’s syndrome also increase a person’s risk of 
dementia. Moreover, lifestyle factors have also been implicated in dementia. The main 
lifestyle risk factors would be physical inactivity, smoking, unhealthy diet, excessive 
alcohol and head injuries. It seems that people who remain active, socially connected 
and mentally engaged are less likely to develop a dementia (10). 
4.1.2. TYPES OF DEMENTIA 
There are a large number of conditions which cause the symptoms of dementia and 
dementia affects people differently. There are a lot of factors that determine the 
impact of dementia on the person, so two people might have the same type of 
dementia, but show different symptomatology. The most common types of dementia 
are drawn below: 
4.1.2.1. Alzheimer’s disease 
AD is the most common cause of dementia and it is a progressive disease. Day-to-day 
memory is the problem that often draws our attention, but the symptomatology might 
also include difficulties in finding the right words, making decisions, solving problems 
or perceiving things in three dimensions. AD etiology and pathophysiology will be 
explained in more detail in sections 4.2 and 4.3. In order to improve the diagnosis, the 
current criteria identifies three stages of AD (6): 
a) Preclinical AD or presymptomatic stage 
At this stage, individuals have measurable changes in the brain, cerebrospinal fluid, 
and/or blood (biomarkers) that indicate the earliest signs of disease, but they have not 
yet developed symptoms such as memory loss (6). 
b) Mild cognitive impairment due to AD 
Since AD is a slow, progressive disorder, with no fixed events that define its onset, it is 
particularly challenging for clinicians to identify transition points for individual 
patients. This predementia phase of AD is referred as mild cognitive impairment (MCI) 
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(11). People with MCI may suffer some forgetfulness or weaknesses that we might 
think are not pathological, but they can be indicative of the problems that the brain is 
having to obtain energy. One of the first characteristics of this cognitive impairment is 
the decrease of the cerebral metabolic rate for glucose (CMRglc) (12). People with AD 
showed reduced CMRglc and some researchers even assure that this is the most 
prevalent abnormality in this disease. This decreased use of the brain fuel mainly takes 
place in the areas involved in memory and learning while the ones involved in visual 
processing and sensory motor skills are not affected. That means that the person is 
going to have his cognitive skills modified, but he or she will be able to walk, see, etc 
(5).  
c) Dementia due to AD 
This stage is characterized by memory, thinking, and behavioural symptoms that 
impair a person’s ability to function in daily life and that are caused by AD-related 
processes. 
4.1.2.2. Vascular dementia 
This dementia is characterised by a decrease in thinking skills caused by conditions that 
block or reduce blood flow to the brain. This inadequate blood flow can damage and 
eventually kill cells anywhere in the body, but as the brain has one of the body’s 
richest networks of blood vessels, it is especially vulnerable. Its symptoms may be 
most obvious when the person has a major stroke. Vascular dementia is considered 
the second most common cause of dementia, accounting for 10% of cases (13).  
4.1.2.3. Mixed dementia 
It refers to the person who has more than one type of dementia. Consequently, the 
person might have a mixture of the symptoms of those types of dementia. For 
example, it is quite common to have both Alzheimer’s disease and vascular dementia 
together. 
4.1.2.4. Dementia with Lewy bodies 
In this particular type of dementia, the death of brain cells is due to the formation of 
tiny abnormal structures inside the brain cells called Lewy bodies. Some of the 
symptoms include alertness, hallucinations and difficulties in judging distances. This 
dementia is closely related to Parkinson’s disease and sometimes people having 
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dementia with Lewy bodies share some symptoms with this disease, including 
difficulty with movement (14). 
4.1.2.5. Frontotemporal dementia (including Pick’s disease) 
The damaged parts of the brain are the front and side ones. Brain cells are also dead 
because of the formation of an abnormal mass of proteins inside them. At first sight, 
the most obvious signs may be changes in personality and behaviour (14).  
Pick’s disease was first described by Czech neurologist and psychiatrist Arnold Pick in 
1892. It is known especially for the aphasia it causes. This can distinguish it from other 
types of frontotemporal dementia, in which behaviour problems and personality 
changes are often a primary first symptom. Like Alzheimer’s disease, Pick’s disease is 
currently untreatable (15).  
 
4.2. ALZHEIMER’S DISEASE ETIOLOGY 
As mentioned before, AD is commonly suffered by people after the age of 65, but 
people under this age can also develop it. In this case, it is called early-onset AD. Since 
AD represents approximately the 70% of the dementia cases, this project will be 
focused in this specific dementia. Below are the main risk factors explained in more 
detail. 
4.2.1. AGE 
Like for the other types of dementia, age is the greatest risk factor for AD. Above 65 
years old, a person’s risk of developing Alzheimer’s disease doubles approximately 
every five years. This leads to the fact that one in six people over 80 years old have 
dementia (4).  
4.2.2. GENDER 
Female sex may also be a risk factor in developing AD, despite the reasons are not 
clear. There are about twice as many women as men over 65 years old with AD, 
regardless of their longevity. It is well-known that young females’ mitochondria are 
protected against amyloid-β toxicity because they generate less reactive oxygen 
species and release less apoptogenic signals than males’ mitochondria. But this 
advantage is lost in old females, who don’t have this protection due to the decrease of 
estrogen levels (16). 
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4.2.3. GENETIC INHERITANCE 
Genetics also take part in our health. The strongest genetic risk factor is 
Apolipoprotein E (ApoE), specifically APOEε4, one of the alleles of the gene that 
codifies for the molecule apolipoprotein E. This molecule transports through the blood 
stream the hydrophobic substances that cannot be transport by themselves (vitamins 
A, D, E, K, cholesterol and fatty acids). As the major component of high-density 
lipoprotein-like (HDL-like) particles in the brain, ApoE facilitates the transfer of 
cholesterol and phospholipid between cells. In the receptor-mediated endocytosis of 
HDL-like particles through low-density lipoprotein (LDL) receptor family, ApoE 
performs as a ligand. Each ApoE isoform has a different structure and function. ApoE2 
has only 1-2% of binding affinity to LDL receptor (LDLR), compared with ApoE3 and 
ApoE4. The structural difference is also attributed to the differential ApoE cleavage 
(17). 
APOEε4 carriers have more risk to develop AD because the genotype affects the 
clearance and aggregation of Aβ. Carriers have even more risk if they have the two 
copies. However, this gene doesn’t cause AD, and it’s not essential to develop the 
dementia. Emerging data suggest that ApoE may also affect AD pathogenesis through 
amyloid β-independent pathways (18–20) (figure 1). ApoE affects cerebral vascular 
function by affecting cerebral blood flow, neuronal-vascular coupling and blood-brain 
barrier (BBB). It also has a role in the metabolism of lipid and glucose and synaptic 
plasticity (17). 
 
Figure 1. ApoE-mediated pathogenic pathways, leading to AD (17). 
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Furthermore, APOEε4 genotype is not associated with insulin resistance, which 
suggests that genotype and glycemic impairment may represent independent risk 
factors for disease conversion (8). 
4.2.4. HEALTH AND LIFESTYLE 
Some medical conditions such as diabetes, stroke and heart problems are known to be 
risk factors for dementia. People who adopt a healthy lifestyle, especially from mid-life 
onwards, are less likely to develop AD. This healthy lifestyle includes physical exercise, 
healthy weight, not smoking, eating a healthy balanced diet and drinking alcohol only 
in moderation. 
 4.2.4.1. Insulin resistance and type 2 diabetes 
Insulin resistance and type 2 diabetes are associated with cognitive decline and 
increased risk for AD. The prevalence of both insulin resistance and AD increase with 
age, and more than half of individuals older than 65 years have either diabetes or 
prediabetes. Studies suggest that diabetes may accelerate conversion from mild 
cognitive impairment to AD (21). It has been established that diabetics have up to a 
65% increased risk of developing AD (22). Insulin is one of the key mediators of 
metabolic homeostasis, since this hormone regulates glucose, energy and lipids. After 
a meal, elevated glucose provokes that the pancreas releases insulin which stimulates 
muscle and adipocytes to take up and utilize glucose, and this way plasma glucose 
levels are reduced. Insulin has three mainly targets: the liver, the muscle and the 
adipose tissue. This hormone reduces the gluconeogenesis in the liver, increases 
glucose uptake by the muscle and reduces lipolysis so the plasma level of free fatty 
acids is reduced. But when there is insulin resistance, it is the other way around: 
glucose production is increased, glucose uptake is reduced and free fatty acids are also 
increased.  
For a long time, it was assumed that insulin signalling has only these peripheral 
actions, but now it is widely accepted that insulin has specific effects in the brain. 
These actions are metabolic, neurotrophic, neuromodulatory and neuroendocrine 
functions (23). Under physiological conditions, insulin binding to its receptor triggers 
phosphorylation of insulin receptor substrate-1 (IRS-1). Through phosphoinositide 3-
kinase (PI3K) activation, glycogen synthase kinase 3 β (GSK3β) is inactivated and so is 
the phosphorylation of protein tau, a neuronal microtubule-associated protein found 
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in axons. This protein is responsible for the polymerization and stabilization of 
microtubules. When there is insulin resistance, GSK3β is activated and the 
hyperphosphorylation of tau is induced. This leads to the formation of neurofibrillary 
tangles (NFTs) and the subsequent cognitive dysfunction (23,24). The importance of 
tau and its phosphorylation in the formation of NFTs will be explained in more detail in 
section 4.3.1.  
Insulin resistance has also been associated with an increased amyloid β (Aβ) deposition 
in the brain, one of the hallmarks of AD. Insulin increased insulin degrading enzyme 
(IDE) expression (25), but in an insulin resistance state, the activity of this enzyme is 
reduced.  This would drive to an increased level of Aβ and cognitive abnormalities 
(26,27).  
Therefore, the link between insulin and AD might be related to the role of insulin in 
brain metabolism and plasticity. There are insulin receptors in brain regions involved in 
memory function, and abnormalities in central nervous system (CNS) insulin signalling 
drive to cognitive alterations. Studies in animal models of insulin resistance have 
concluded that it exacerbates Aβ and tau phenotypes including hyperphosphorylated 
tau, which are the characteristic alterations in neurodegenerative processes (26,28–
34). 
4.2.4.2. Diet 
Although it is well known that some lifestyle-related factors are associated with 
cognitive decline, diet in particular has become the object of intense research in 
relation to neurodegenerative diseases (35). Recent findings demonstrate that 
maintaining a healthy diet may impact on many of the possible risk factors for 
cognitive decline and the model to follow seems to be the Mediterranean diet (MeDi) 
(36). It is thought that dietary factors that affect AD risk are those that have an effect 
on the amyloid cascade (37). That is why our diet choice has a key role in our cerebral 
health (5). Thus, it has been shown that diets rich in cholesterol and saturated fats 
increased the deposition of Aβ  and the risk of developing AD (38,39). However, these 
diets were not low-carbohydrate diets because cholesterol was added to the diet 
without reduction of other components. In fact, it has been recently demonstrated 
that a diet rich in saturated fats and low in carbohydrates can actually reduce levels of 
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Aβ (40). This diet induces hepatic production of ketone bodies and, as explained in 
section 4.5, it is known as a ketogenic diet (KD).  
On the other hand, epidemiological evidence has suggested a possible association 
among fish consumption, monounsaturated fatty acids (MUFA) and polyunsaturated 
fatty acids (PUFA) (particularly, n-3 PUFA) and reduced risk of cognitive decline, AD 
and dementia (36). On the contrary, high carbohydrate intake might cause AD by two 
mechanisms (41): 
1. By disturbing lipid homeostasis and compromising the integrity of cellular 
membranes. This would cause a decrease in membrane proteins activity such 
as glucose transporters, leading to a reduction in the utilization of glucose as a 
source of energy in the brain.  
2. By inducing mild chronic elevated insulin signalling, which accelerates cellular 
damage. High carbohydrate diets are well known to stimulate insulin signalling 
and chronic stimulation of this pathway may lead to an alteration of lipid 
metabolism. This drives to inappropriate lipid environments in neurons, mis-
cleavage of amyloid precursor protein (APP) and the resulting inhibition of 
cellular trafficking, and increasing the risk of developing AD (40). Moreover, it 
has been shown that apoE4 and high carbohydrate diets alter lipid metabolism 
in a similar manner, reducing lipoprotein lipase activity and thus increasing 
triglyceride-rich lipoprotein levels, which suggests a common mechanism for 
the etiology of AD (41). 
 
4.3. PATHOPHYSIOLOGICAL BASES OF ALZHEIMER’S DISEASE 
4.3.1. “AMYLOID HYPOTHESIS” 
Amyloid beta is a group of peptides generated as cleavage products from 36 to 
43 amino acids and with a molecular mass of approximately 4kDa. They derive from 
the amyloid precursor protein (APP), a transmembrane protein. The “amyloid 
hypothesis” is the most influential model of the pathology of AD proposed over the 
last 25 years and, according to it, accumulation of Aβ in the brain is the primary 
influence driving AD pathogenesis. 
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Figure 2. The sequence of pathogenic events leading to AD (42) 
The deposition of Aβ in brain is one of the characteristics of a pathologic brain because 
it drives to a lack of communication between the neurons since the synapses are 
altered. Normal amounts of Aβ in healthy brains don’t modify the cognitive function. 
Actually, Aβ depresses synaptic activity and without this depression, synaptic activity 
could become excessing, leading to excitotoxicity. Data suggest that Aβ has important 
physiological functions and, further, that it should only be regarded as toxic when its 
production and degradation are imbalanced (43). It has been established that this 
deposition could be due to an overproduction of Aβ or to a lack of degradation of it. 
Last studies suggest that the second hypothesis is more likely (43). Several proteases 
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are shown to degrade Aβ including insulin degrading enzyme (IDE), angiotensin 
converting enzyme (ACE), neprilysin (NEP) and endothelin-converting enzyme-1 (ECE-
1). So, several proteases are involved in Aβ degradation in vitro, but the two major 
enzymes in vivo are IDE and NEP. IDE has been shown to degrade Aβ and to influence 
brain Aβ levels in vivo. Since extracellular Aβ aggregation is one of the hallmarks of AD 
pathology according to the amyloid hypothesis and Aβ is not found in cytosol, 
extracellular IDE may play a key role in the clearance of Aβ and can relate to the AD 
pathology (5,44). 
Several peptides have been highlighted as substrates of IDE, including insulin, insulin-
like growth factor I and II, amylin, Aβ and others. Under physiological conditions, IDE is 
secreted at high levels from the microglial cells and degrades Aβ extracellularly. This 
activity has shown to be lower in AD brains. As IDE has different substrates in vivo with 
different affinities, the imbalance of the substrates could affect the degradation 
process by IDE and, consequently, the pathogenesis of AD. As mentioned before (pg 
12), it has been suggested that insulin resistance leads to reduced IDE activity. This 
could be explained because insulin resistance leads to compensatory hyperinsulinemia 
and therefore to increased brain insulin level. Due to substrate competition, increased 
insulin would inhibit the ability of IDE to degrade Aβ properly, causing Aβ neurotoxicity 
and AD (5,25).  
Another histopathological hallmark of AD is neurofibrillary tangles (NFTs). These NFTs 
are insoluble twisted fibers found inside the neurons, made up of aggregates of tau 
protein. Tau was first discovered as a microtubule-associated protein (MAP) that 
stimulates tubulin assembly into microtubules in the brain. There was not much 
research interest in tau protein until a decade later, when it was found to make up the 
paired helical filaments (PHFs) of these NFTs in AD brains. Tau is modified post-
translationally by several ways in both normal and pathological conditions 
(phosphorylation, glycosylation, ubiquitination, glycation, polyamination, nitration, 
truncation and aggregation). But the major component of PHFs in AD is abnormally 
hyperphosphorylated tau. The normal level of tau phosphorylation is a consequence of 
dynamic regulation of tau kinases and tau phosphatases. However, the causes leading 
to abnormal hyperphosphorylation of tau are still not fully understood (45). It has 
been known that inherited mutation in APP and its protease (presenilin) cause early-
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onset Aβ deposition and this is followed by accumulation of tangles containing 
filaments of wild-type tau (46,47). In contrast, mutations in the tau gene lead to a form 
of frontotemporal dementia without Aβ accumulation. So, Aβ accumulation can lead 
to progressive tau deposition and its phosphorylation (48), but the converse has not 
been clearly demonstrated in humans (42). 
Tau O-GlcNAcylation was found to be decreased in AD brain, and this decrease was 
correlated to tau hyperphosphorylation. This acylation is directly regulated by glucose 
metabolism: impaired glucose metabolism may cause decreased tau O- 
GlcNAcylation which, in turn, leads to hyperphosphorylation of tau and neurofibrillary 
generation (45).  
4.3.2. METABOLIC SYNDROME 
Metabolic Syndrome (MetS) is considered a major public health problem and is one of 
the few clinical syndromes that affects a large portion of the general population which 
is potentially reversible by established interventions. The most commonly used 
definition for MetS in the United States is the one described by the National 
Cholesterol Education Program Third Adult Treatment Panel (NCEP ATP III), which is 
the presence of three or more of the following criteria: 
• Abdominal obesity: waist >102 cm (>40 in) for men or >88 cm (>35 in) for women 
• Triglycerides ≥150 mg/dL 
• HDL <40 mg/dL for men or <50 mg/dL for women 
• Blood pressure ≥130/≥85 mmHg or current use of anti-hypertensive medications 
• Fasting glucose level ≥110 mg/dL 
Most studies report that MetS and its components have a negative impact on 
cognition. However, findings may vary by sex (49). MetS could be one of the causes 
leading to MCI, the first stage of AD. Furthermore, MetS is often the result of long 
term insulin resistance due to an excessive consumption of some food components 
(especially refined carbohydrates) aggravated by the modern lifestyle stress, lack of 
sleep and poor quality of it, and insufficient physical activity (5). 
All the indicators established by the NCEP ATP III might suggest that the body is not 
properly assimilating carbohydrates and it is reacting with abnormally high insulin or 
glucose levels. The main metabolic alteration linked with AD is the insulin resistance. 
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Insulin not only regulates glucose and lipid metabolism in the brain, but also plays an 
important role in learning and memory (50). As mentioned in section 4.2.4.1, insulin 
resistance causes GSK3β activation and the hyperphosphorylation of tau is induced. 
This leads to the formation of NFTs and the subsequent cognitive dysfunction (23,24).  
4.3.3. BRAIN ENERGY DEFICIT HYPOTHESIS 
Despite the brain represents only a 2 percent of the total body mass, it requires more 
than the 20 percent of the daily energy intake. The brain is one of the most 
metabolically active organs in the body. As a consequence, the food we consume has a 
direct impact on brain function. Glucose is the primary energy source for the brain, but 
in prolonged fasting, the brain uses ketone bodies, that can replace glucose perfectly. 
The average adult human brain metabolizes about 110 to 145 g/day of glucose. 
However, in AD there is a decline of a 17 to 24% in the cerebral metabolic rate for 
glucose (CMRglc) and low CMRglc has been correlated with low cognitive scores (51). 
AD is, above all, a brain fuel metabolism dysfunction, which means that it results from 
the brain’s inability to generate or use properly the energy (5). A bulk of studies have 
shown that the blood-brain barrier (BBB) is impaired in AD resulting in an altered 
expression of some transporters, including the down-regulation of glucose transporter. 
The primary fuel for the brain, as mentioned before, is glucose. It must be taken from 
the blood and transported across the BBB by the specific glucose transporters (GLUTs) 
due to the inability of neurons to synthesize or store it. In AD, the expression of these 
transporters is decreased and the brain has an energy deficit (1).  
This explanation may indicate that the amyloid cascade hypothesis in not valid for 
sporadic AD, but that the formation of both, amyloidogenic derivatives and 
hyperphosphorylated tau protein is downstream the origin of this neurodegenerative 
disease.  So, a decline in brain metabolic activity regardless of etiology, seems to be 
the underlying cause of cognitive decline and dementia (34,52,53). There is evidence 
that the reductions in the availability of both glucose/energy and insulin contribute to 
the formation of amyloidogenic derivatives and hyperphosphorylated tau protein. 
Decreased metabolic activity increases beta secretase (BACE) which, in turn, increases 
Aβ deposition as a secondary response. BACE is an enzyme involved in the cleavage of 
APP, resulting in the formation of Aβ. A study established that chronically induced 
cerebral hypoperfusion in rats resulted in increased BACE and Aβ and poorer learning 
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in a Morris water maze (54). To sum up, Aβ overproduction is believed to be a 
secondary phenomenon that may result in further clinical decline. According to this 
hypothesis, the goal would be to identify the factors that cause this decreased 
metabolic activity that leads to neuronal death, and then find ways to increase it. The 
interaction of different macronutrients, in particular fats and carbohydrates, is known 
to influence the metabolic state (36). It might be that the way the body normally copes 
with condition of low glucose availability could be exogenously applied to AD. This way 
might be the use of ketone bodies (KBs). KBs metabolism becomes the main source of 
alternative energy as a results of carbohydrate deficiency and increased availability of 
fatty acids from lipolysis. The two KBs that can replace glucose in the brain are β-
hydroxybutyrate (βHB) and acetoacetate (AcAc). The lack of success in the therapy of 
AD moved the focus of research to functional dysregulation of brain metabolism, 
mitochondrial homeostasis and excitatory and inhibitory neuronal signaling (1). A 
possible “metabolic therapy” is widely explained in section 4.5. 
 
4.4. CURRENT ALZHEIMER’S DISEASE TREATMENT 
Alzheimer’s disease eventually leads to the death of affected individuals at an average 
of nine years after diagnosis. For the last three decades, the standard treatments for 
AD have been acetylcholinesterase inhibitors, highlighted below, together with other 
drugs to manage the mood disturbance, agitation and psychosis that usually appear in 
the later stages. In the recent years, memantine, also explained below, has been 
widely used. Although the efforts to find a suitable treatment, all of these drugs show 
modest symptomatic effects and it is believed that the major barrier to effective 
treatments is the lack of full understanding of the mechanism of AD (45). 
There are two different groups of drugs approved in Spain by the competent 
administration, the Agencia Española de Medicamentos y Productos Sanitarios 
(AEMPS).  
4.4.1. ACETYLCHOLINESTERASE INHIBITORS 
All cholinesterase inhibitors work in a similar way, but one might suit a certain 
individual better than another, particularly in terms of side effects experienced. The 
mechanism of action of these drugs is by increasing the amount of Acetylcholine (ACh), 
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a neurotransmitter responsible, among others, of the memory capacity. These drugs 
increase ACh by inhibiting its degradation since they are acetylcholinesterase 
inhibitors, the enzyme responsible of ACh’s degradation. The improvement of 
cholinergic function is accomplished by this increase in ACh concentration. So the 
effect may lessen as the disease progresses and fewer cholinergic neurons remain 
functionally intact (55). Tacrine was the first acetylcholinesterase inhibitor approved to 
treat AD, but it was withdrawn from the market for its hepatotoxicity.  
4.4.1.1. Donepezil 
Donepezil may improve mental function and this includes the ability to think and 
remember, or slow the loss of these abilities in people who have AD. However, as 
mention before, it will not cure AD or prevent the loss of mental abilities (56). 
Donepezil is a reversible and non-competitive acetylcholinesterase inhibitor. 
4.4.1.2. Rivastigmine 
Rivastigmine is also a reversible and non-competitive cholinesterase inhibitor. But, 
unlike the others, rivastigmine inhibits both butyrylcholinesterase and 
acetylcholinesterase. Butyrylcholinesterase is mainly found outside the central nervous 
system (CNS) and the fact that this drug inhibits the two cholinesterase reduces its side 
effects. One important characteristic about this drug is that it does not use the 
cytochrome route to be eliminated and this is very useful for people who suffer 
different pathologies and receive different treatments.     
4.4.1.3. Galantamine 
This drug is a benzazepine. It is a cholinesterase 
inhibitor that has been used to reverse the muscular 
effects of gallamine triethiodide and tubocurarine, 
and has been studied as a treatment for AD and 
other CNS disorders. It is a reversible and 
competitive acetylcholinesterase inhibitor, but also 
an allosteric modulator of the nicotinic receptor, which promotes the cholinergic 
activity. This mechanism of action is because galantamine is not structurally related to 
other acetylcholinesterase inhibitors (55) (figure 3). However, some side effects are 
common with Donepezil: leg cramps and urinary incontinence.  
Figure 3. Galantamine (55) 
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4.4.2. NMDA ANTAGONIST: MEMANTINE 
Glutamate is another neurotransmitter, an endogenous chemical messenger which 
transmits signals across a chemical synapse. Glutamate is released in excessive 
amounts when brain cells are damaged by AD. This causes the brain cells to be 
damaged further. Memantine protects brain cells by blocking the effects of excess 
glutamate so the mechanism of action is different from that of donepezil, rivastigmine 
and galantamine. The neurotransmitter glutamate activates several classes of 
metabotropic receptors and three major types of ionotropic receptors: alpha-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), kainate and N-methyl-D-
aspartate (NMDA). It is suggested that glutamate receptors, in particular of the NMDA 
type, are overactivated in a tonic rather than a phasic manner. Such continuous, mild, 
chronic activation ultimately leads to neuronal damage/death (57). Memantine has a 
great clinical efficiency and it is indicated in serious AD cases. It also has effects in 
other receptors like the dopaminergic and that is why neurologic and psychologic 
effects such as confusion or hallucinations could be observed.   
4.4.3. NEW PERSPECTIVES 
There have not been new drugs approved for the treatment of AD since 2003 (58), but 
new therapies are urgently needed to treat affected patients and to prevent, defer, 
slow the decline, or improve the symptoms of AD. It has been estimated that the 
overall frequency of the disease would be decreased by nearly 50% if the onset of the 
disease could be delayed by 5 years (59). Most candidate therapies are disease-
modifying therapies (DMTs) (70% across all phases). This term refers to a drug that can 
modify or change the course of the disease. The remainder candidate therapies are 
symptomatic agents directed at cognitive enhancement (14%) or treatment of 
neuropsychiatric symptoms (13%) and agents with undisclosed mechanisms of action 
(MOAs) (2%) (59). 
4.4.3.1. Solanezumab 
Solanezumab is a humanized monoclonal antibody against Aβ and it was designed to 
increase the clearance from the brain of soluble Aβ. The results recently published 
showed that it does not significantly affect cognitive decline (60).  
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4.4.3.2. Tideglusib 
This drug is an inhibitor of glycogen synthase kinase 3 (GSK3), the responsible of tau 
phosphorylation. A phase II trial of tideglusib established that it is acceptably safe, but 
produced no clinical benefit (61).  
4.4.3.3. Lithium 
Lithium inhibits site-specific AD-like tau phosphorylation in living neurons and it has 
been suggested that chronic lithium treatment similar to that prescribed for manic-
depressive patients might slow down tau hyperphosphorylation in the brains of 
patients with AD (62). Furthermore, a systematic review and meta-analysis has 
indicated that lithium treatment may have beneficial effects on cognitive performance 
in subjects with MCI and AD (63). 
4.4.3.4. Metabolic treatment for AD 
AD neurodegeneration has been associated with different abnormalities like energy 
imbalance, dysregulated lipid and carbohydrate metabolism, cytokine mediated 
inflammation, increased oxidative stress, cell death and vascular degeneration. These 
problems are also present in type 2 diabetes so some scientifics support that AD may 
be managed by similar or identical therapeutic strategies. According to some 
researchers, therapeutic options for treating AD as a metabolic disorder are mainly 
three: lifestyle changes, anti-inflammatory/anti-oxidant measures and insulin signalling 
support. The first one mainly includes aerobic physical exercise, weight training and 
adopting a healthful diet. These measures that preserve insulin responsiveness would 
protect against cognitive impairment and neurodegeneration. There are 
epidemiological studies that suggest that individuals who chronically take anti-
inflammatory or anti-oxidant drugs had lower risks for developing cognitive 
impairment and AD (64). The last therapeutic option is insulin signalling support. The 
brain needs insulin for different reasons such as to support metabolism, neuronal 
survival, synaptic plasticity or neuroprotection. Insulin could be administrated by 
different routes. Since insulin crosses the blood-brain barrier (BBB), various routes 
could modulate brain metabolism (34).  
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4.5. A DIFFERENT TREATMENT APPROACH TO ALZHEIMER’S DISEASE 
As mentioned before, it has been hypothesized that Alzheimer’s disease is mainly a 
problem in the metabolism of the cerebral fuel and this leads the brain to a situation 
of energy deficit. That is why a metabolic strategy should be considered as a 
treatment. Specifically, for example, a change in the diet and lifestyle.  
Ketogenic diet (KD) 
The KD is a high-fat, adequate-protein and low-carbohydrate diet. The fact that 
carbohydrates are nearly eliminated means that the body has minimal dietary sources 
of glucose (65). This diet is also known as keto diet, low carb diet, low carb high fat 
(LCHF) among others. Glucose is the easiest molecule for our body to convert and use 
as energy so it is the one that would be chosen over other sources. Since glucose is 
being used as a primary energy source, fats are not needed and are stored (66). This is 
what usually happens because according to most dietary guidelines (figure 4), the main 
components of a healthy diet are carbohydrates. These guidelines were developed as 
part of the Strategy for Nutrition, Physical Activity and the Prevention of Obesity 
(NAOS Strategy) of the Spanish Agency for Consumer Affairs, Food Safety and Nutrition 
of the Spanish Ministry of Health, Social Services and Equality. However, as mentioned 
before, these are not the recommendations in a ketogenic diet. The nutrient intake in 
a KD should be something around 70% of fats, 25% of proteins and 5% of 
carbohydrates (figure 5). 
By lowering the intake of carbohydrates, the body is induced into a state known as 
ketosis or ketogenesis, which is a natural process the body initiates to help us survive 






Figure 5. Approximate proportions in a ketogenic 
diet 
Figure 4. Macronutrients proportions in general 
recommendations 
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which are produced from the breakdown of fats in the liver. The three ketone bodies 
are acetoacetate (AcAc), β-hydroxybutyrate (βHB) and acetone; and they are produced 
from acetyl-CoA in the mitochondrial matrix of liver cells. The aim of this diet is to 
force the body into this metabolic state. KD diet was developed to mimic a starvation 
response in animals without reducing calories to harmful levels (40). Ketones are 
supposed to be a second line fuel for our body, but this is just said because glucose is 
the most favourite fuel for our body. However, ketone bodies are a more efficient fuel 
than glucose. Furthermore, ketosis induces a moderate uncoupling state and less 
oxidative efficiency compared to glucose oxidation (67).  During starvation, ketone 
bodies are the major energy source (75%) for the brain. 
KD was set up in the first decade of the last century to treat refractory epilepsy and 
then applied with success to treat other neurological diseases. The proved 
effectiveness of the KD in childhood refractory epilepsy and the early metabolic 
dysfunction observed in MCI, paved the way to evaluate the possible therapeutic role 
of dietary metabolic approaches to AD and other neurodegenerative diseases (1). 
There are different types of ketogenic diets. The classic KD was designed in 1923 for 
the treatment of epilepsy by Dr. Russell Wilder and it approximately results in 90% of 
total calories intake from fat, 6% from protein and 4% from carbohydrates. As it is very 
difficult to maintain this KD, some variants of the KD have been published. The main 
alternative one is the Medium-Chain Triglyceride ketogenic diet (MCTKD), which is 
characterised for less lipid energy intake (45%) and this fat is mainly short fatty acids. 
These shorter fatty acids have a quick metabolism that results in more efficient 
generation of ketone bodies allowing to assume a greater proportion of carbohydrates 
(1), but it is still limited to approximately 29% of energy (68). Medium-chain fatty acids 
are able to cross the BBB and provide an alternative energy source for brain neurons 
and astrocytes. 
The neuroprotective effects of ketone bodies have been associated with different 
mechanisms (1): 
• Increasing intracellular adenosine triphosphate (ATP) availability 
• Reducing reactive oxygen species (ROS) generation by mitochondrial complex I 
• Inhibiting mitochondrial permeability transition 
• Stimulating mitochondrial biogenesis, resulting in stabilized synaptic function 
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• Altering metabolism of neurotransmitters such as glutamate and gamma-
amino butyric acid (GABA) 
• Activating energy-sensing signalling pathways 
AD etiopathogenesis has been linked to oxidative stress, neuroinflammation, 
mitochondrial impairment, hypometabolism and BBB disruption (69–71). Therefore, it 
is believed that all these mechanisms set before would be effective to treat AD.  
The findings of recent investigations have suggested that caloric restriction prevents 
age-related neuronal damage and may be useful in the prevention and treatment of 
AD (72). Animal models provide insight into the underlying mechanisms of many 
diseases, included AD, and they have been useful in the preclinical evaluation of 
potential treatments. The results obtained in animal models vary. Some data suggest 
that KD may play an important role in enhancing motor performance in mice, but have 
minimal impact on the phenotype of murine models of amyloid or tau deposition (73). 
Another study with aged dogs, a natural model of amyloidosis, suggested that short-
term administration of medium-chain triglycerides improves energy metabolism in the 
aged canine brain (74). Furthermore, some clinical trials have been done to analyse the 
efficacy of ketone bodies in patients with AD. For example, the effects of an increase in 
plasma ketone body levels on cognitive functions were investigated in older adults 
with memory disorders. It was observed that this increase was moderated by ApoE 
genotype. In APOEε4 carriers, levels continued to rise, while levels in ApoE4 non-
carriers remained constant. On cognitive testing, medium chain triglycerides (MCT) 
treatment facilitated performance on the Alzheimer’s Disease Assessment Scale-
Cognitive Subscale (ADAS-cog) for ε4− subjects, but not for ε4+ subjects. Thus, higher 
ketone values were associated with greater improvement in paragraph recall with MCT 
treatment relative to placebo across all subjects (75). In another study, ketosis was 
induced by a diet very low in carbohydrates and the findings suggested that this diet 
can improve memory function in older adults with increased risk for AD (76).  
According to the data we have access to, a dietary intervention represents a relatively 
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Possible complications of a ketogenic diet 
A KD should be established for a long period. However, the restrictions in the diet 
might make people think that this diet is difficult to achieve. Therefore, an important 
complication to face in a KD treatment is the lack of adherence.  
A lot of the food recommended in a KD provide us cholesterol such as eggs, butter or 
animal protein. Most of this food has also choline, an essential nutrient for 
acetylcholine production which, as mentioned before, plays a key role in the memory 
and learning. However, this food is also rich in cholesterol, which may lead to 
hyperlipidemia. Previous studies have indicated that hyperlipidemia may be a risk 
factor for dementia and AD. Thus, some results suggested a link between high midlife 
cholesterol levels and increased dementia risk, but later studies found no association 
between midlife cholesterol and subsequent dementia (77). Cholesterol is a chemical 
essential compound for the cell membranes and hormones like estrogen and 
testosterone. The 80% of this substance is generated in the liver and the rest comes 
from our diet. After a meal, cholesterol in the diet is absorbed through the small 
intestine and metabolized and stored in the liver. As the body requires cholesterol, the 
liver releases it. High blood cholesterol is usually caused by lifestyle factors, such as 
diet, in combination with our genes. Untreated high blood cholesterol can build up in 
deposits called plaque in the blood vessels, known as atherosclerosis. If this high level 
becomes chronic or uncontrolled, it can cause serious complications including carotid 
artery disease, coronary heart disease (angina or heart attack), peripheral artery 
disease or stroke (78). So, although we know that cholesterol is essential in our body, 
we should be aware about the possible complications of chronic high cholesterol 
consumption and determine plasma cholesterol levels regularly, especially in people 
above their 40s.  
Furthermore, it is important to mention what ketoacidosis is. Diabetic ketoacidosis is a 
pathological metabolic state characterized by extreme ketosis which cannot be 
adequately regulated due to a lack of insulin in patients with type 1 diabetes. The 
resulting pH imbalance may be fatal. However, this metabolic abnormality is not 
possible in nutritional ketosis (“physiological ketosis”) induced by KD. The evaluation 
of side effects of ketogenic diets in patients with AD is difficult due to the small 
number of available clinical trials, but major adverse reactions have not been reported 
Alzheimer’s disease as a metabolic pathology: new approaches 
Final degree project 
- 24 - 
 
in the literature. In some studies, transient gastrointestinal effects like diarrhea, 
dyspepsia and flatulence were reported in patients receiving a formulation of medium 
chain triglycerides (79,80). Investigations assess the supplementation of the normal 
glucose supply with ketone bodies which are produced by the body during glucose 




Alzheimer’s disease is a complex disorder, influenced by a number of different factors. 
That’s why I strongly believe that a multifactorial approach would be needed. The 
drugs that we have nowadays are treating the neurotransmitters deficit, because the 
memory problem is mainly caused by this lack of acetylcholine. By this mechanism, 
these drugs just control the symptoms of the disease, managing behavioural 
manifestations and slowing down their progression. However, these drugs are not a 
cure for AD, and we are not treating the onset of the dementia.  
According to all the research done about the pathogenesis of the AD, one of the 
mechanisms leading to this type of dementia is hyperinsulinemia and impaired glucose 
metabolism. To summarise, this chronic condition would provoke: 
• Aβ accumulation because, as explained in section 4.3.1, IDE degrades both insulin 
and Aβ. Under a situation of hyperinsulinemia, Aβ degradation by IDE would be 
reduced. 
• Neurofibrillary tangles, caused by impaired glucose metabolism which leads to a 
decrease of tau-O-GlyNAcylation that causes an hyperphosphorylation of tau. 
• Metabolic Syndrome that would end with a mild cognitive impairment and its 
subsequent dementia. 
Having plasma glucose levels under control does not assure that there is not any 
abnormality because the problem may be also the hyperinsulinemia. Our body 
generates insulin in order to reduce the glucose in our blood. So, the best way to 
reduce the amount of blood glucose and, as a consequence, correct the 
hyperinsulinemia, is reducing the quantity of glucose in our diets. As said before, 
glucose is not the only way of obtaining energy for our body and it is not the most 
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effective. Ketones can provide approximately 40-60% of the energy that our brain 
needs (5). A promising treatment for AD is a change in the diet that implies a decrease 
in carbohydrate intake which would subsequently reduce the hyperinsulinemia. 
Moreover, in AD brain there is a situation of energy deficit due to a reduced ability to 
obtain glucose from plasma. A diet low in carbohydrate and high in lipids would 
generate ketones and the brain would be able to obtain energy from this source. 
However, we should be aware of the complications of this diet and make sure that it 
will be used under medical supervision. 
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